FDA CLEARANCE OF AMPLIA’S IND FOR PANCREATIC CANCER TRIAL IN US

HIGHLIGHTS The US FDA has cleared Amplia’s Investigational New Drug (IND) Application for a clinical trial of narmafotinib in the USA The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in the USA MELBOURNE, Australia, Jan….